ArticleBiomedica : revista del Instituto Nacional de Salud2025
Classification of human epidermal growth factor receptor 2 expression in cancerous breast tissue through artificial intelligence
Article in Biomedica : revista del Instituto Nacional de Salud, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction. Histological and molecular analysis of breast tissue is essential for the diagnosis, prognosis, and treatment of breast cancer. Key biomarkers include progesterone and estrogen receptors, as well as the human epidermal growth factor receptor 2 (HER2). HER2 overexpression indicates an aggressive subtype of breast cancer but enables targeted therapies that improve survival rates. However, its evaluation faces challenges, ranging from sample quality to interpretation variability. The College of American Pathologists classifies HER2 overexpression into four categories, but variations around the 10% expression threshold can lead to misinterpretations. Objective. To present an automated technique for classifying HER2-overexpressing cells in histological slides. Materials and methods. The Cross-Industry Standard Process for Data Mining (CRISP-DM) methodology was applied using samples of 89 patients from the Unidad de Diagnóstico en Patología, covering all four HER2 expression levels. Deep learning techniques were employed, leveraging neural networks and vision transformer models through transfer learning. Additionally, a usability evaluation was conducted on the final version of the software. Results. The ViT-B/16 model achieved a classification accuracy of 90,65%, while the tool was evaluated with an acceptable level of satisfaction in its clinical application. Conclusion. Artificial intelligence demonstrated high accuracy and consistency in HER2 classification, reducing diagnostic variability and improving objectivity. However, further optimization of processing efficiency is required for broader applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.